<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Hydroxychloroquine and CQ are quinine analogues that have been widely used in the treatment of malaria and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Their in vitro antiviral properties have been known for decades
 <xref rid="bib69" ref-type="bibr">69</xref>, 
 <xref rid="bib70" ref-type="bibr">70</xref>, 
 <xref rid="bib71" ref-type="bibr">71</xref> and more recently have been studied in SARS-CoV.
 <xref rid="bib72" ref-type="bibr">
  <sup>72</sup>
 </xref> Repeated studies have found that the in vitro antiviral activity of CQ has failed to translate to clinical outcomes in other viral diseases (reviewed in reference 
 <xref rid="bib73" ref-type="bibr">73</xref>). Double-blind RCTs to date have failed to find CQ’s efficacy as an antiviral in influenza, dengue, and chikungunya.
 <xref rid="bib74" ref-type="bibr">74</xref>, 
 <xref rid="bib75" ref-type="bibr">75</xref>, 
 <xref rid="bib76" ref-type="bibr">76</xref>
</p>
